{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T18:25:11Z","timestamp":1773253511596,"version":"3.50.1"},"reference-count":75,"publisher":"The Korean Association for the Study of the Liver","issue":"4","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"funder":[{"name":"MSD"},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100018854","name":"SIRTEX","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100018854","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["e-cmh.org"],"crossmark-restriction":true},"short-container-title":["Clin Mol Hepatol"],"published-print":{"date-parts":[[2023,10,1]]},"abstract":"<jats:p>Emergence of multi-targeted kinase inhibitors (MTIs) and immune checkpoint inhibitors (ICI) have changed the landscape of management in hepatocellular carcinoma (HCC). Combination therapy involving ICI has superseded sorafenib as the first-line treatment option for advanced HCC due to their superior response rates and survival benefits based on recently published phase III trials. However, the role of first-line lenvatinib remains uncertain as no prospective trials have compared its efficacy with ICI in advanced HCC. Several retrospective studies have shown that first-line lenvatinib may not be inferior to ICI combination. Indeed, a growing body of evidence suggests that ICI treatment is associated with inferior treatment outcome in non-viral HCC patients, questioning the supremacy of ICI treatment in all patients and rendering first-line lenvatinib as a potential preferred treatment option. Furthermore, in high-burden intermediate-stage HCC, accumulating evidence supports first-line lenvatinib, or in combination with transarterial chemoembolization (TACE), as a preferred treatment option over TACE alone. In this Review, we describe the latest evidence surrounding the evolving role of first-line lenvatinib in HCC. <\/jats:p>","DOI":"10.3350\/cmh.2023.0114","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T07:17:44Z","timestamp":1684999064000},"page":"909-923","update-policy":"https:\/\/doi.org\/10.3350\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["The evolving role of lenvatinib at the new era of first-line hepatocellular carcinoma treatment"],"prefix":"10.3350","volume":"29","author":[{"given":"Landon L.","family":"Chan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8998-5480","authenticated-orcid":true,"given":"Stephen L.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1902","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0708857"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.48.4410"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.45.8372"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.54.3298"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.53.7746"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30207-1"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)32453-9"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1717002"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30937-9"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1915745"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.4_suppl.379"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)32517-x"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/638747"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(21)00110-2"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1010726"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-22-143"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra1703481"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-022-00841-0"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10173932"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199603143341104"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.4240\/wjgs.v13.i10.1267"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1092401"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2011.12.009"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2013.02.026"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1177\/000313481408000723"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13184584"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5123"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2023.01.134"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/978-3-031-08552-9","volume-title":"Baveno VII - Renewing consensus in portal hypertension","author":"de Franchis","year":"2022"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.11.019"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13531"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14977"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13537"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049717"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13592"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.14193"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.15_suppl.4073"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14071747"},{"key":"ref42","first-page":"9","volume-title":"Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population","author":"Casadei-Gardini","year":"2023"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.737767"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s330195"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13718"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.08.015"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2018.11.005"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.08.031"},{"key":"ref49","volume-title":"Finn Reviews Phase 3 Trials of Lenvatinib in Advanced HCC"},{"key":"ref50","volume-title":"P-108: Impact of dose adjustment on clinical outcome of lenvatinibtreated patients with advanced hepatocellular carcinoma (HCC)","author":"Chan","year":"2022"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00326-6"},{"key":"ref52","first-page":"450","volume-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","author":"Pfister","year":"2021"},{"key":"ref53","first-page":"100591","volume-title":"Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis","author":"Rimini","year":"2022"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0424"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.13536"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00392"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.4240\/wjgs.v14.i6.528"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.14740\/jocmr2496w"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2007.01712.x"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)30010-2"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1159\/000480208"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.07.020"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-0919"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24644"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11081084"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1159\/000487148"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(08)70284-5"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.4_suppl.417"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.4_suppl.tps487"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2022.40.4_suppl.tps498"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1159\/000526163"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.1159\/000512781"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.4_suppl.507"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-021-03031-9"}],"container-title":["Clinical and Molecular Hepatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/e-cmh.org\/upload\/pdf\/cmh-2023-0114.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-cmh.org\/journal\/view.php?doi=10.3350\/cmh.2023.0114","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/e-cmh.org\/upload\/pdf\/cmh-2023-0114.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T06:20:30Z","timestamp":1697005230000},"score":1,"resource":{"primary":{"URL":"http:\/\/e-cmh.org\/journal\/view.php?doi=10.3350\/cmh.2023.0114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,1]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"URL":"https:\/\/doi.org\/10.3350\/cmh.2023.0114","relation":{},"ISSN":["2287-2728","2287-285X"],"issn-type":[{"value":"2287-2728","type":"print"},{"value":"2287-285X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,1]]},"assertion":[{"value":"2023-03-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-05-25","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-01","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}